Actinium Pharmaceuticals (NYSE: $ATNM) to Host Webinar to Provide Update on Actimab-A Phase 2 Clinical Trial

Actinium Pharmaceuticals (NYSE: $ATNM) to Host Webinar to Provide Update on Actimab-A Phase 2 Clinical Trial

Webinar to be Held on Tuesday, September 27, 2016 at 9:00 AM ET

Webinar to feature Principle Investigator Joseph Jurcic, M.D., Professor of Clinical Medicine and Director of the Hematologic Malignancies Section of the Hematology/Oncology Division at Columbia University Medical Center

NEW YORK - September 21, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company will host a webinar on Tuesday, September 27, 2016 at 9:00 AM ET to provide an update on the Actimab-A Phase 2 Clinical Trial. Details of the webinar are below:

Date: Tuesday, September 27, 2016 
Time: 9:00 AM ET 
Webinar Link:

https://onecast.thinkpragmatic.com/ses/awQiM-9OD7Iysoul6ZD6BQ~~

"Since presenting our Phase 1 data on June 1, 2016, we have made progress on our Actimab-A program", stated Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals. "We look forward to providing an update on the Actimab-A Phase 2 trial that will include the protocol changes that have been agreed to by the FDA."

Dr. Joseph Jurcic, M.D., Principle Investigator for the Actimab-A Phase 2 trial said, "Actimab-A is intended to treat patients over the age of 60 that are newly diagnosed with acute myeloid leukemia, which is a patient population with significant unmet medical needs. The results from the Actimab-A Phase 1 clinical trial showed an encouraging safety and efficacy profile that gives us great excitement for the Phase 2 clinical trial of Actimab-A."

The Actimab-A Phase 2 clinical trial is expected to begin in 2016 and will enroll 53 patients bringing the total number of patients in this Phase 1/2 Actimab-A trial to 71. This multi-center, open-label, single-arm Phase 2 trial will enroll patients newly diagnosed with AML who are over the age of 60. The Company will also be incorporating into the Phase 2 trial protocol changes including the removal of low dose cytarabine, the mandated use of granulocyte colony-stimulating factors (GCSF) and the mandated use of Hydroxyurea based on the findings from its peripheral blast (PB) burden hypothesis which was derived from the two Phase 1 clinical trials conducted with Actimab-A in its Hum195-Alpha clinical program.

Based on evidence that suggests that peripheral blasts prevent Actimab-A from reaching the bone marrow at optimal doses, the Company has mandated the use of Hydroxyurea to reduce the PB burden in patients above a certain key threshold. PB burden will serve as an inclusion criteria for the Phase 2 trial but it is not expected to exclude patients due to the ability of Hydroxyurea to reduce peripheral blasts. The end point of the Phase 2 trial will be complete response rate at up to 42 days after Actimab-A administration, where complete response is defined as complete remission (CR) or complete remission with incomplete platelet recovery (CRp). A formal interim analysis is expected to occur in mid-2017.

Read this release in full at http://www.investorideas.com/CO/ATNM/news/2016/09211ClinicalTrial.asp

About Actimab-A

Actimab-A, Actinium's most advanced alpha particle immunotherapy (APIT) program, is being prepared for a Phase 2 clinical trial for patients newly diagnosed with AML over the age of 60. Actimab-A is being developed as a first-line therapy and it has attracted support from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy profile. Actimab-A consists of the monoclonal antibody, HuM195, and the radioisotope, actinium-225. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. HuM195 is the humanized version of M195 and is a monoclonal antibody that targets CD33, which is abundantly found on myeloid leukemia cells. Both the alpha particle technology and HuM195 were initially developed at Memorial Sloan Kettering Cancer Center. Actimab-A is a second-generation therapy from the Company’s HuM195-Alpha program, which has now been studied in almost 90 patients in four clinical trials.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Source: Actinium Pharmaceuticals

Visit this company: www.actiniumpharma.com

More info on ATNM at Investorideas.com Visit: http://www.investorideas.com/CO/ATNM/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.

Disclosure: One month news , social media and marketing Actinium Pharmaceuticals, Inc. (ATNM) by third party IRTH Communications starting September 19, 2016: three thousand per month.

Actinium Pharmaceuticals (NYSE: $ATNM) Selects Vector Oncology as its Clinical Research Organization for Actimab-A Phase 2 Trial

Actinium Pharmaceuticals (NYSE: $ATNM) Selects Vector Oncology as its Clinical Research Organization for Actimab-A Phase 2 Trial

NEW YORK - September 20, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has selected Vector Oncology as its Clinical Research Organization (CRO) for its anticipated Actimab-A Phase 2 clinical trial.

"We are delighted to be working with Vector Oncology for our upcoming Phase 2 clinical trial," stated Dragan Cicic, M.D., Actinium’s Chief Medical Officer. "Vector Oncology displayed an expertise in hematology clinical trials with an emphasis on Phase 2 studies, which gives us great confidence in our selection. We look forward to working with Vector Oncology and to benefiting from their robust clinical capabilities."

Sean L. Hart, Executive Vice President and Managing Director at Vector Oncology said, "Vector Oncology is excited to be working with Actinium as a member of this important team. Since our first interaction with Actinium, all team members involved have committed to getting this important product in the hands of oncology professionals as soon as possible to advance the research efforts. We very much look forward to an exciting future together."

The Company recently completed a Phase 1 trial with Actimab-A in 18 patients newly diagnosed with Acute Myeloid Leukemia (AML) who are above the age of 60. The Phase 1 trial was a dose escalation study with fractionated dosing levels of Actimab-A ranging from 0.5 µCi/kg/fractionated dose to 2.0 µCi/kg/fractionated dose. Actinium announced that the dose for the Phase 2 clinical trial will be two doses of Actimab-A at 2.0 µCi/kg/fractionated dose one week apart, the highest dose level from the Phase 1 trial.

The Actimab-A Phase 2 clinical trial is expected to begin in 2016 and will enroll 53 patients bringing the total number of patients in this Phase 1/2 Actimab-A trial to 71. This multi-center, open-label, single-arm Phase 2 trial will enroll patients newly diagnosed with AML who are over the age of 60.The Company will also be incorporating into the Phase 2 trial protocol changes including the removal of low dose cytarabine, the mandated use of granulocyte colony-stimulating factors (GCSF) and the mandated use of Hydroxyurea based on the findings from its peripheral blast (PB) burden hypothesis which was derived from the two Phase 1 clinical trials conducted with Actimab-A in its Hum195-Alpha clinical program.

Based on evidence that suggests that peripheral blasts prevent Actimab-A from reaching the bone marrow at optimal doses, the Company has mandated the use of Hydroxyurea to reduce the PB burden in patients above a certain key threshold. PB burden will serve as an inclusion criteria for the Phase 2 trial but it is not expected to exclude patients due to the ability of Hydroxyurea to reduce peripheral blasts. The end point of the Phase 2 trial will be complete response rate at up to 42 days after Actimab-A administration, where complete response is defined as complete remission (CR) or complete remission with incomplete platelet recovery (CRp). A formal interim analysis is expected to occur in mid-2017.

Sandesh Seth, Actinium’s Executive Chairman said, "The selection of Vector Oncology as our CRO marks an important step in the development of Actimab-A. The Phase 2 Actimab-A trial is the second Phase 2 trial from our HuM195-Alpha program, albeit with a second generation, much superior product candidate and tantalizing results from the Phase 1 portion that should bode well for the progress of this trial. With the revised protocol, PB burden hypothesis and strengthened clinical development team we look forward to the Phase 2 trial of Actimab-A and working with Vector Oncology to ensure efficient and timely trial execution."

Read this release in full at http://www.investorideas.com/CO/ATNM/news/2016/09201Actimab-A.asp

About Vector Oncology

Vector Oncology is a leader in the design and delivery of care based oncology research and data analytics. Utilizing our comprehensive Oncology Data Warehouse and proprietary Patient Care Monitor (PCM) patient engagement and outcomes platform, our experienced project teams, medical experts and health economics and outcomes scientists design and deliver high-quality projects generating real world evidence and insight. With some of the most experienced medical, scientific, operational, and executive teams in late stage research, Vector Oncology is uniquely positioned to meet the demand to demonstrate product value in terms of economic impact, clinical effectiveness and tolerability, and patient reported outcomes (PRO). For more information, please visit www.vectoroncology.com.

About Actimab-A

Actimab-A, Actinium's most advanced alpha particle immunotherapy (APIT) program, is being prepared for a Phase 2 clinical trial for patients newly diagnosed with AML over the age of 60. Actimab-A is being developed as a first-line therapy and it has attracted support from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy profile. Actimab-A consists of the monoclonal antibody, HuM195, and the radioisotope, actinium-225. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. HuM195 is the humanized version of M195 and is a monoclonal antibody that targets CD33, which is abundantly found on myeloid leukemia cells. Both the alpha particle technology and HuM195 were initially developed at Memorial Sloan Kettering Cancer Center. Actimab-A is a second-generation therapy from the Company’s HuM195-Alpha program, which has now been studied in almost 90 patients in four clinical trials.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Vector Oncology
Sean Hart
Executive Vice President and Managing Director
shart@vectoroncology.com

Source: Actinium Pharmaceuticals

Visit this company: www.actiniumpharma.com

More info on ATNM at Investorideas.com Visit: http://www.investorideas.com/CO/ATNM/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.

Disclosure: One month news , social media and marketing Actinium Pharmaceuticals, Inc. (ATNM) by third party IRTH Communications starting September 19, 2016: three thousand per month.

Gopher Protocol's (OTCQB: $GOPH) Guardian Patch Location Technology Successfully Tracks Object Within 50 Square Mile Radius in First Live Testing Demonstration

Gopher Protocol's (OTCQB: $GOPH) Guardian Patch Location Technology Successfully Tracks Object Within 50 Square Mile Radius in First Live Testing Demonstration

SAN DIEGO, CA - September 20, 2016 (Investorideas.com Newswire) Gopher Protocol Inc. (OTCQB:GOPH) ("Gopher" and the "Company"), a development-stage Company which specializes in the development of real-time, heuristic-based mobile technologies, and its partner, Guardian Patch LLC, announce that they have successfully completed the first live demonstration and testing of the Guardian Patch (the "Patch") location technology that works with or without GPS. The demonstration of the "GOPHERINSIGHT™" circuit prototype device, which took place in San Diego, California on September 14, 2016 between 10:00 AM - 11:00 AM PT, proved range coverage of approximately 50 square miles. The Patch is a "stick-on" device that provides its users with the capability to protect and track objects, such as valuable personal belongings, children and loved-ones, and even family pets, through a mobile application. The demonstration of the Patch was completed in the San Diego area within a densely populated urban area. More than 1,000 active followers watched the live demonstration using the Guardian Mobile App.

The Guardian Patch's Demonstration Route 

The Guardian Patch's Demonstration Route

"Today we demonstrated our Patch technology's power and capabilities. We were pleased to provide the live public demonstration as part of our on-going mobile technology development sharing program. The Patch integrates key technologies and features to provide for an exceptional tracking experience and includes a new generation of truly portable and untethered devices which we believe are necessary in our modern world," said Company CTO, Dr. Danny Rittman. Dr. Rittman continued, "Our GopherInsight mobile technology provides users not only with connectivity and safety, but also with computing power enhancements and database capabilities compatible with our mobile world. We also plan to add a live demo portal to guardianpatch.com in the near future, which will allow live Patch viewing on Guardian Map applications."

The Patch prototype unit contains the Company's GOPHERINSIGHT™ integrated circuit technology. The Patch prototype consists of mobile units and base units. The mobile unit's real-time position is shown on the mobile app. The system provides an accurate location and progress presentation of the Patch mobile unit via the mobile map. The prototype system is currently reporting about the mobile unit's location every few seconds in order to test a real-time positioning system. The web-based program may in the future provide statistical information about the mobile units, including, but not limited to, travel distance, cities visited, travel time and more. This data would be used in the future to enhance customers' vital statistics for personal purposes. In addition, other electrical factors are measured and studied, such as electrical power consumption, transmission intervals, terrain and weather effects and more. In parallel, the Company is constantly enhancing and improving the system's software to handle large amount of mobile units and their coverage.

Special attention is also given to human engineering of user friendly UI (User Interface) of the mobile application software and the web-based control program. Additionally, a robust database management system is being designed in order to manage large numbers of mobile units efficiently.

The Patch prototype, which the Company hopes will arrive in the consumer markets sometime in 2017, is a unique location technology that works with or without GPS. It is a stick-on tracking device that protects and tracks objects, from a phone to a laptop to a loved one or a pet, through a mobile app.

Read this release in full at http://www.investorideas.com/CO/GOPH/news/2016/09201LiveTesting.asp

About Guardian Patch

The Guardian Patch (the "Patch"), potentially arriving in consumer markets in 2017, is a unique location technology that works with or without GPS. The Patch is a "stick-on" device that provides its users with the capability to protect and track objects, a loved-one or even a pet, through a mobile application. Download the Patch app, register your patch, and track anything that you own on your mobile device or on our designated website. Register the Patches of your family members and friends to receive alerts in the event of an emergency. Peel the Patch off and the Patch acts as a beacon, sending out a signal and notifying anyone who has registered the user's Patch.

About Gopher Protocol Inc.

Gopher Protocol Inc. (OTCQB: GOPH) (“Gopher” and the "Company") (http://gopherprotocol.com/) is a development-stage company developing a real-time, heuristic-based mobile technology.  Upon development, the technology will consist of a smart microchip, mobile application software and supporting software that will run on a server.  The system contemplates the creation of a global network.  Gopher believes this will be among the first system that is developed using a human, heuristic-based analysis engine.  Since the core of the system will be its advanced microchip technology that will be capable of being installed in any mobile device worldwide, Gopher expects that this will result in an internal, private network between all mobile devices utilizing the microchip by providing mobile technology for computing power enhancement, advanced mobile database management/sharing and other additional mobile features.

Corporate Site: http://gopherprotocol.com

Press page/ press kit - http://gopherprotocol.com/?page_id=228

Consumer and product website for Guardian Patch: http://www.guardianpatch.com/

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements".  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact:

Danny Rittman CTO
Gopher Protocol Inc.
VM Only - 888-685-7336

Media: press@gopherprotocol.com

Visit this company: http://gopherprotocol.com/

More info on GOPH at Investorideas.com Visit: http://www.investorideas.com/CO/GOPH/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GOPH is a PR , social media and publishing client and compensates Investorideas.com ( three months effective April 4, 2016- three thousand five hundred per month )

More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Gainey (TSXV: $GNC.V; OTCQX: $GNYPF) Exploration Update; Completion of first three Diamond Drill holes at the El Colomo Gold-Silver Project in Mexico

Gainey (TSXV: $GNC.V; OTCQX: $GNYPF) Exploration Update; Completion of first three Diamond Drill holes at the El Colomo Gold-Silver Project in Mexico

Vancouver, British Columbia - September 20, 2016 (Investorideas.com Newswire) Gainey Capital Corp. (TSXV: GNC; OTCQX: GNYPF) recently reported that the Phase 1 Drilling campaign has completed the first three Diamond Drill holes at the El Colomo Gold-Silver Project in Mexico. The first of the three holes targeting the La Nueva Victoria Mineralized Zone has been sampled and shipped to ALS Labs Vancouver, BC for analysis and the other two holes are currently being processed at the Company’s core logging facility to be submitted shortly. Preliminary results from these drill holes are anticipated within the next few weeks.

Furthermore, the Company is pleased to announce that the program continues to advance with the commencement of drilling on the first of four targets at the La Higuerita/El Arrayan Mineralized Zones.

Gainey’s exploration team, led by Rafael Gallardo of Minera Cascabel S.A. de C.V., notes that though they have encountered two serious weather systems in the region, the program has not met any serious delays, and drilling progress has continued on the target zones. David Coburn, CEO of Gainey, commented, "we are looking forward to the first set of drilling results over the next 2-3 weeks. The Exploration Team has done an excellent job meeting their objectives given they have encountered challenging weather conditions."

The Company recently upgraded its exploration team with the addition of David Hladky, P.Geo. to the Technical Advisory Board, who is also the Company’s acting Qualified Person as defined by NI 43-101, please see the Company’s news release on July 26, 2016 for full details. Mr. Hladky’s previous position was with Cayden Resources Inc. as the Qualified Person and one of the leaders in the exploration of the Morelos Sur and El Barqueno projects in Mexico, that were successfully sold to Agnico Eagle Mines for $205 Million in 2014.

The Company also reports the grant of up to an aggregate 2.5 million common share purchase options, exercisable at a price of $0.20 per share, to its directors, officers, employees and consultants.

Read this release in full at http://www.investorideas.com/CO/GNC/news/2016/09201Mexico.asp

About Gainey Capital Corp.

Gainey Capital is a gold and silver exploration, development and mineral processing company exploring an aggregate of 192-km2 strategically located in the gold/silver-rich Sierra Madre Occidental Trend in western Mexico. The company’s processing centre, located outside of Huajicori, in Nayarit, Mexico, is capable of processing up to 300 tons of mineralized material per day and the company has the capability to upgrade to 600 tons per day with a low capital expenditure. Additional information on Gainey Capital, its current operations and its vision is available on the Company’s website at www.gaineycapital.com or from info@gaineycapital.com.

ON BEHALF OF THE BOARD OF DIRECTORS

"David Coburn"

David Coburn, Chief Executive Officer

For information, please contact the Company:

Phone: 480-347-8904
E-mail: info@gaineycapital.com
Website: www.gaineycapital.com

FORWARD LOOKING STATEMENTS: This press release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date such statements were made. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has reviewed or accepts responsibility for the adequacy or accuracy of this Release.

Visit this company: www.gaineycapital.com

More info on GNC.V at Investorideas.com Visit: http://www.investorideas.com/CO/GNC/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.

Disclosure : Gainey Capital Corp. has retained Investor ideas for 3 months starting September 16 2016 for news and social media marketing ; three thousand six hundred plus stock options - see more info at http://www.investorideas.com/About/News/Clientspecifics.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

NXT-ID, Inc. (NASDAQ: $NXTD) To Exhibit at Money20/20, Leading Payments & FinTech Conference, October 23-26

NXT-ID, Inc. (NASDAQ: $NXTD) To Exhibit at Money20/20, Leading Payments & FinTech Conference, October 23-26

WorldVentures to Showcase New Smart Card at NXT-ID Booth

MELBOURNE, Florida - September 19, 2016 (Investorideas.com Newswire) NXT-ID, Inc. (NASDAQ:NXTD) (NXTDW) ("NXT-ID" or the "Company"), a company focused on the growing mobile commerce announces it will be presenting at Money20/20, in Las Vegas, October 23-26, 2016 in Booth 3532. Money20/20 is one of the largest global events covering payments and financial services innovation for connected commerce.

NXT-ID, Inc will be presenting its portfolio of secure mobile and payment technology and meeting with industry leaders to explore new opportunities and ventures.

WorldVentures, will also be showcasing its new smart card developed by NXT-ID. The smart card, currently in alpha testing, is intended to allow WorldVentures' travel club members to load up to 10 records (credit cards, loyalty cards, identity cards, and other data), use as a payment method in the same way as a credit card, where accepted earn loyalty points at select restaurants worldwide, and engage and interact socially with other DreamTrips Members worldwide through its communication features.

Read this release in full at http://www.investorideas.com/CO/NXT/news/2016/09191Exhibit.asp

About Money 2020

Money20/20 organizes the largest global events enabling payments and financial services innovation for connected commerce at the intersection of mobile, retail, marketing services, data and technology. With 10,000+ attendees, including more than 1,000 CEOs, from over 3,000 companies and 75 countries, expected at its 2016 U.S. event, Money20/20 is critical to realizing the vision of disruptive ways in which consumers and businesses manage, spend and borrow money. Money20/20 will be held at The Venetian in Las Vegas, October 23-26, 2016.

In just four years, Money20/20 fundamentally disrupted the status quo and established an entirely new and groundbreaking scale and standard for industry events. https://www.money2020.com

About WorldVentures

WorldVentures sells travel club memberships providing a diverse set of lifestyle products and experiences. The company's goal is to help Independent Representatives, DreamTrips™ Members and employees achieve more fun, freedom and fulfillment in their lives. WorldVentures uses the direct sales model to go to market with active Representatives and Members in 29 markets. http://www.worldventures.com

About NXT- ID Inc. - Mobile Security for a Mobile World

NXT-ID, Inc.'s innovative MobileBio® solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio suite of biometric solutions that secure consumers' mobile platforms. With extensive experience in Biometric Identity Verification, Security and Privacy, Encryption and Data Protection, Payments, Miniaturization and Sensor technologies, the Company partners with industry leading companies to provide solutions for modern payment and IoT applications.

http://nxt-id.com/, http://wocketwallet.com/.

Forward-Looking Statements for NXT-ID: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

NXT- ID Inc Contact:

Corporate info: info@nxt-id.com

Media:

D. Van Zant
+1-800-665-0411
press@nxt-id.com

Visit this company: nxt-id.com; 3d-id.net; wocketwallet.com/

More info on NXTD at Investorideas.com Visit: http://www.investorideas.com/CO/NXT/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: As of October 1, 2015 NXT-Id renewed for one year –five thousand per month and fifteen thousand 144 restricted shares for PR, media and marketing. http://www.investorideas.com/About/Disclaimer.asp and http://www.investorideas.com/About/News/Clientspecifics.asp

Actinium Pharmaceuticals (NYSE: $ATNM) to Present at Ladenburg Thalmann 2nd Annual Healthcare Conference

Actinium Pharmaceuticals (NYSE: $ATNM) to Present at Ladenburg Thalmann 2nd Annual Healthcare Conference

Actinium to Present on Tuesday, September 27, 2016 at 1:00 PM ET

Management Will be Available for 1-on-1 Meetings with Conference Attendees

NEW YORK - September 19, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company will be presenting at the Ladenburg Thalmann 2nd Annual Healthcare Conference being held on Tuesday, September 27, 2016 at the Sofitel Hotel in New York, New York. Details regarding Actinium's presentation are below:

Event: Ladenburg Thalmann 2nd Annual Healthcare Conference 
Location: Sofitel Hotel, New York, New York 
Presentation Time: 1:00 PM ET 
Room: Montmartre, Track 5

Management will be available for 1-on-1 meetings with conference attendees. To schedule a meeting with management please contact Steve O'Loughlin, Vice President, Finance and Corporate Development at soloughlin@actiniumpharma.com.

Actinium's presentation can be viewed live via webcast through the following link http://wsw.com/webcast/ladenburg2/atnm.

The presentation will be archived and available for playback via the investor relations page of Actinium's website http://ir.actiniumpharma.com/ir-calendar.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial.

Read this release in full at http://www.investorideas.com/CO/ATNM/news/2016/09191AnnualHealthcareConference.asp

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Source: Actinium Pharmaceuticals

Visit this company: www.actiniumpharma.com

More info on ATNM at Investorideas.com Visit: http://www.investorideas.com/CO/ATNM/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.

Disclosure: One month news , social media and marketing Actinium Pharmaceuticals, Inc. (ATNM) by third party IRTH Communications starting September 19, 2016: three thousand per month.